10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
The chart shows the growth of an initial investment of $10,000 in 10x Genomics, Inc. Class A Common Stock, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
10x Genomics, Inc. Class A Common Stock (TXG) has returned 36.91% so far this year and 213.18% over the past 12 months. Looking at the last ten years, TXG has achieved an annualized return of -8.45%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of 10x Genomics, Inc. Class A Common Stock (TXG) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 23.85% | 14.11% | -5.35% | 3.28% | ||||||||
| 2025 | 3.45% | -26.28% | -18.33% | -4.56% | 14.82% | 20.50% | 17.16% | 6.95% | -14.92% | 16.09% | 37.60% | -11.41% |
| 2024 | -23.90% | 11.29% | -19.57% | -22.62% | -15.40% | -15.40% | 5.84% | 12.48% | -3.96% | -28.91% | -2.03% | -8.88% |
| 2023 | 24.91% | 0.57% | 16.35% | -5.00% | 0.48% | 6.87% | 12.08% | -16.57% | -21.76% | -14.10% | 24.13% | 30.08% |
| 2022 | -35.24% | -17.00% | -5.77% | -37.42% | 9.17% | -11.45% | -11.74% | -17.15% | -12.40% | -6.15% | 37.00% | -6.78% |
| 2021 | 20.86% | 1.45% | 0.90% | 8.94% | -9.13% | 8.79% | -6.43% | -4.90% | -17.47% | 11.22% | -5.39% | -4.51% |
| 2020 | 18.83% | -12.66% | -22.53% | 33.56% | -0.69% | 14.53% | 10.43% | 15.78% | 8.18% | 7.90% | 11.35% | -6.99% |
| 2019 | -6.67% | 14.83% | 10.94% | 15.64% |
The charts below present risk-adjusted performance metrics for 10x Genomics, Inc. Class A Common Stock (TXG) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of TXG compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current 10x Genomics, Inc. Class A Common Stock volatility is 4.83%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 1.04B | 918.64M | 965.14M | 1.03B | 1.02B | 929.34M | 605.92M |
| Equity Attributable To Parent (USD) | 796.33M | 710.13M | 741.04M | 805.74M | 817.57M | 739.07M | 420.08M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - |
| Equity (USD) | 796.33M | 710.13M | 741.04M | 805.74M | 817.57M | 739.07M | 420.08M |
| Other Non-current Liabilities (USD) | - | - | - | - | - | - | 93.07M |
| Long-term Debt (USD) | - | - | - | - | - | - | 29.72M |
| Noncurrent Liabilities (USD) | 91.59M | 90.87M | 96.94M | 92.28M | 90.90M | 72.14M | 122.79M |
| Other Current Liabilities (USD) | 98.22M | 71.11M | 81.32M | 76.68M | 61.38M | 98.03M | 37.63M |
| Wages (USD) | 42.50M | 33.62M | 30.11M | 32.68M | 31.63M | 15.38M | 12.39M |
| Accounts Payable (USD) | 12.73M | 12.91M | 15.74M | 21.60M | 17.35M | 4.71M | 13.03M |
| Current Liabilities (USD) | 153.45M | 117.63M | 127.16M | 130.96M | 110.36M | 118.13M | 63.05M |
| Liabilities (USD) | 245.04M | 208.50M | 224.10M | 223.24M | 201.26M | 190.27M | 185.84M |
| Other Non-current Assets (USD) | 67.87M | 65.93M | 72.93M | 81.76M | 76.35M | 82.14M | 76.26M |
| Intangible Assets (USD) | 62.33M | 15.67M | 16.62M | 22.86M | 25.40M | - | - |
| Fixed Assets (USD) | 226.71M | 252.65M | 279.57M | 289.33M | 169.49M | 72.84M | 48.82M |
| Noncurrent Assets (USD) | 356.91M | 334.25M | 369.12M | 393.95M | 271.24M | 154.98M | 125.08M |
| Other Current Assets (USD) | 628.11M | 501.28M | 522.32M | 553.41M | 687.63M | 744.41M | 465.57M |
| Inventory (USD) | 56.34M | 83.11M | 73.71M | 81.63M | 59.97M | 29.96M | 15.27M |
| Current Assets (USD) | 684.45M | 584.39M | 596.02M | 635.04M | 747.59M | 774.37M | 480.84M |
| Assets (USD) | 1.04B | 918.64M | 965.14M | 1.03B | 1.02B | 929.34M | 605.92M |
Cathie Wood's Ark Invest made surprisingly few purchases last week, buying shares in only three companies: Figma, Arcturus Therapeutics, and 10x Genomics. Despite significant declines from their highs, Wood sees value in these growth-stage companies across design software, biotech, and genomics sectors.
Ark Invest unveiled its 'big ideas' for 2026 through cryptic ARKmoji images, challenging users to interpret six investment themes: AI Agents, Genomics, Space Race (reusable rockets), Cryptocurrencies/Tokenization, Robotics, and The Great Acceleration. The firm highlighted portfolio holdings aligned with each theme, spanning multiple sectors from biotech to defense and space technology.
Global tumor transcriptomics market projected to grow from $6.02 billion in 2024 to $8.71 billion by 2030, driven by rising cancer prevalence and genomic sequencing advancements, with spatial transcriptomics emerging as a key technological trend.
Lancaster Investment Management acquired a new $7.27 million position in 10x Genomics during Q3 2025, purchasing 621,779 shares representing 3.1% of its assets under management.
The global Single-cell Analysis Market is projected to grow from USD 3.90 billion in 2024 to USD 12.29 billion by 2032, with a 13.61% CAGR, driven by increasing cancer research, precision medicine, and advanced genomics technologies.
The report highlights the rapid advancements in the molecular diagnostics for cancer market, driven by trends like personalized medicine, pharmacogenomics, and liquid biopsy. It profiles over 140 companies and provides extensive data and forecasts to aid decision-making in this evolving global market.
The global single cell multiomics market is expected to grow from $3.78 billion in 2023 to $18.90 billion by 2033, at a CAGR of 19.58%. The growth is driven by increasing demand for advanced research solutions, rise in biomedical research and precision medicine, and technological advancements.
The global spatial proteomics market is expected to reach $199.8 million by 2030, driven by the growing demand for precision medicine and personalized therapies, particularly in oncology. Key growth drivers include increasing investment in proteomics research and the rising prevalence of chronic diseases.
The global RNA transcriptome profiling test market is expected to grow at a CAGR of 14.5% and reach a valuation of US$ 37,383.8 million by 2034, driven by increasing investments in biotechnology and genomics for the detection of chronic diseases.
Cathie Wood, the co-founder and CEO of Ark Invest, has been slowing the pace of her portfolio moves lately. However, she still made some notable purchases on Monday, increasing her existing positions in Amazon, GitLab, and 10x Genomics.
